Back to top

Myriad Genetics: (MYGN)

(Market Close from NSDQ)

 Add to portfolio

 ZacksTrade Now

$35.76 USD

35.76
590,782

+0.21 (0.59%)

Updated Mar 27, 2015 03:59 PM ET

Volume: 590,782

Open: $35.43

Prior Close: $35.55

Zacks Rank : 3-Hold [?]     3    

Style Scores [?] : Growth: B | Value: B | Momentum: B

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Zacks Style Score A
Growth Score A
Value Score A
Momentum Score A
Income Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The three scores are based on the trading styles of Growth, Value, and Momentum.

Growth Score A
Value Score A
Momentum Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Balance Sheet

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Growth Score A
Value Score A
Momentum Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

Fiscal Year End for MYRIAD GENETICS falls in the month of June.

All items in Millions except Per Share data.

6/30/2014 6/30/2013 6/30/2012 6/30/2011 6/30/2010
Assets          
Cash & Equivalents 186 372 341 346 403
Receivables 85 98 63 51 48
Notes Receivable 0 0 0 0 0
Inventories 24 5 12 6 0
Other Current Assets 27 9 7 15 23
Total Current Assets 322 484 422 418 474
Net Property & Equipment 35 28 24 23 23
Investments & Advances 84 159 114 71 85
Other Non-Current Assets 0 22 19 0 0
Deferred Charges 3 29 31 26 9
Intangibles 374 70 73 73 0
Deposits & Other Assets 5 13 8 0 2
Total Assets 824 804 691 611 594
Liabilities & Shareholders Equity 6/30/2014 6/30/2013 6/30/2012 6/30/2011 6/30/2010
Notes Payable 0 0 0 0 0
Accounts Payable 23 18 10 11 9
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 56 44 33 22 19
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 2 2 1 0
Total Current Liabilities 81 65 45 34 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 24 11 10 10 9
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 105 75 55 44 36
Shareholders Equity 6/30/2014 6/30/2013 6/30/2012 6/30/2011 6/30/2010
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 718 697 648 604 567
Retained Earnings 2 31 -13 -39 -10
Other Equity -2 -0 -0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 719 729 636 567 558
Total Liabilities & Shareholder's Equity 824 804 691 611 594
Total Common Equity 719 729 636 567 558
Shares Outstanding 74.80 79.60 84.80 85.70 97.70
Book Value Per Share 9.61 9.15 7.50 6.61 5.71

Fiscal Year End for MYRIAD GENETICS falls in the month of June.

All items in Millions except Per Share data.

12/31/2014 9/30/2014 6/30/2014 3/31/2014 12/31/2013
Assets          
Cash & Equivalents 187 182 186 212 354
Receivables 87 87 85 86 88
Notes Receivable 0 0 0 0 0
Inventories 20 25 24 19 0
Other Current Assets 26 41 27 21 13
Total Current Assets 320 335 322 338 455
Net Property & Equipment 46 43 35 33 31
Investments & Advances 42 54 84 66 135
Other Non-Current Assets 0 0 0 0 23
Deferred Charges 0 0 3 0 30
Intangibles 368 371 374 375 70
Deposits & Other Assets 5 5 5 5 13
Total Assets 782 809 824 816 757
Liabilities & Shareholders Equity 12/31/2014 9/30/2014 6/30/2014 3/31/2014 12/31/2013
Notes Payable 0 0 0 0 0
Accounts Payable 17 26 23 19 18
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 41 41 56 51 46
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 1 1 2 4
Total Current Liabilities 60 68 81 72 67
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 5 0 8 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 25 24 14 13
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 88 97 105 94 81
Shareholders Equity 12/31/2014 9/30/2014 6/30/2014 3/31/2014 12/31/2013
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 735 731 718 703 663
Retained Earnings -37 -17 2 19 12
Other Equity -4 -2 -2 -0 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 694 712 719 722 676
Total Liabilities & Shareholder's Equity 782 809 824 816 757
Total Common Equity 694 712 719 722 676
Shares Outstanding 72.90 73.00 74.80 72.90 74.70
Book Value Per Share 9.52 9.76 9.61 9.91 9.05